サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1739381

標的化ドラッグデリバリーの世界市場

Targeted Drug Delivery

出版日
ページ情報
英文 168 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.36円
標的化ドラッグデリバリーの世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 168 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

標的化ドラッグデリバリーの世界市場は2030年までに249億米ドルに達する見込み

2024年に100億米ドルと推定される標的化ドラッグデリバリーの世界市場は、2024～2030年の分析期間においてCAGR 16.5%で成長し、2030年には249億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである心血管疾患は、CAGR14.5%を記録し、分析期間終了時には86億米ドルに達すると予測されます。肺疾患分野の成長率は、分析期間のCAGRで16.9％と推定されます。

米国市場は26億米ドルと推定、中国はCAGR 15.6％で成長予測

米国の標的化ドラッグデリバリー市場は2024年に26億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに39億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは15.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.9%と14.4%と予測されています。欧州では、ドイツがCAGR約12.3%で成長すると予測されています。

世界の標的化ドラッグデリバリー市場- 主要動向と促進要因のまとめ

なぜ標的化ドラッグデリバリーが現代医療における治療精度と全身的安全性を変革するのか？

標的化ドラッグデリバリーシステムは、薬剤を疾患組織や細胞に特異的に誘導することで、全身への曝露や関連する副作用を最小限に抑え、治療薬の投与方法に革命をもたらしています。健常組織に影響を与えることが多い従来の全身療法とは異なり、標的アプローチは作用部位における薬物濃度を改善し、治療効果を高め、標的外毒性を軽減します。この転換は、治療の特異性が患者の転帰に大きく影響する腫瘍学、神経学、免疫学において特に重要です。

標的化ドラッグデリバリーの魅力は、臨床効率だけでなく、投与回数を減らし、バイオアベイラビリティを高め、血液脳関門や腫瘍微小環境などの生物学的障壁を克服する可能性にあります。薬物の局在性を高めることで、これらのシステムは慢性疾患、遺伝性疾患、複雑な病態の管理方法を再定義し、一般化医療から精密医療への移行を支えています。個別化治療の需要が高まり続ける中、標的送達は医薬品の革新と患者中心の治療にとってますます中心的な役割を果たすようになっています。

ナノテクノロジー、バイオマテリアル、スマートキャリアはどのように標的化ドラッグデリバリープラットフォームを強化しているのか？

ナノテクノロジーとバイオマテリアルの開発により、リポソーム、デンドリマー、高分子ナノ粒子、抗体薬物複合体など、薬物の安定性を向上させ、放出動態を制御し、選択的標的化を促進する高度に設計されたキャリアの開発が可能となっています。これらのシステムは、リガンド、抗体、ペプチドで表面機能化することができ、疾患細胞上に発現する受容体に特異的に結合することで、受容体を介した取り込みとペイロードの細胞内送達を高い精度で行うことができます。

また、pH、酵素、温度などの生理的刺激に反応し、疾患組織内の特定の条件下でのみ薬物が活性化されるようなスマートデリバリーシステムも開発されています。このような刺激応答性プラットフォームは、薬物制御を強化し、早期分解を抑え、局所的な治療作用をサポートします。エクソソームベースのデリバリーやCRISPRを搭載したナノ粒子などの新たな技術革新は、生物学的適合性と分子レベルの制御を組み合わせることで、標的デリバリーのフロンティアを押し広げ、これまでアクセスできなかった病態を治療する新たな道を開いています。

標的化ドラッグデリバリーソリューションの需要を牽引している治療分野とデリバリールートは？

部位特異的な化学療法、免疫療法、放射性医薬品の必要性から、標的化ドラッグデリバリーの最大の応用分野は依然として腫瘍学です。抗体薬物複合体やナノ粒子ベースの製剤のような治療技術は、選択的腫瘍ターゲティングを可能にし、治療反応率を向上させ、全身的副作用を軽減しています。同様に、血液脳関門を通過することが従来の薬剤にとって重要な課題であった中枢神経系（CNS）疾患においても、標的デリバリーが普及しつつあります。

腫瘍学と神経学にとどまらず、自己免疫疾患、感染症、希少遺伝性疾患が高成長分野として浮上しています。全身をターゲットとする場合は依然として静脈内投与が主流であるが、局所的あるいは徐放性の用途では経口、経鼻、経皮、埋め込み型のルートが開発されています。疾患特異的なニーズに合わせた送達様式の拡大により、標的システムの汎用性が高まり、より広範な適応症と患者集団で使用できるようになっています。

薬事規制、市場アクセス、臨床転化は商業化にどのような影響を与えているか？

標的化ドラッグデリバリー製品は、その新規メカニズム、複合構造、潜在的な安全性懸念のために、複雑な規制経路を通過しなければならないです。FDAやEMAのような機関は、薬物動態学、毒性プロファイリング、製品の特徴づけといった側面に焦点を当てながら、ナノメディシンや配合剤に関するガイダンスを改良しています。規制当局との早期連携、確かな臨床エビデンス、Quality-by-design（QbD）アプローチは、承認を迅速化し、規模に応じた再現性を確保するために不可欠になりつつあります。

市場参入は、費用対効果、製造の拡張性、臨床での採用にも同様に左右されます。標的治療薬には高い開発コストがかかることが多いが、治療成績を改善し、下流の治療負担を軽減する能力は、良好な医療経済性を支えることができます。科学的イノベーションと商業的実現可能性の橋渡しをするために、医薬品開発企業、デバイス企業、デリバリー技術プロバイダー間のコラボレーションが一般的になりつつあります。実世界のデータと個別化診断が拡大するにつれて、標的化ドラッグデリバリーソリューションに対する支払者と臨床医の受け入れは、世界のヘルスケア市場で牽引力を増しています。

標的化ドラッグデリバリー市場の成長を促進する要因とは？

標的化ドラッグデリバリー市場は、製薬技術革新が精密医療に軸足を移し、医療制度が全身的負担を最小限に抑えながら有効性を最大化する治療法を求めるにつれて、急速に成長しています。ナノキャリア工学、生体分子ターゲティング、薬物コンジュゲーション技術の進歩により、複数の疾患カテゴリーにおいて治療の可能性が広がっています。同時に、個別化された組織特異的治療の有望性が、規制上のインセンティブ、学術研究、商業的パートナーシップと整合しつつあります。

今後の市場開拓の勢いは、開発者がいかに効率的にデリバリー・イノベーションを治療パイプラインに統合し、進化する規制基準を満たし、臨床的・経済的価値を実証できるかにかかっています。治療パラダイムがより個別化されたメカニズムに基づく治療へとシフトする中、標的化ドラッグデリバリーはテクノロジー、生物学、患者中心のケアの接点で成長を牽引する、次世代医療の基盤となる存在となる準備が整っています。

セグメント

疾患タイプ（心血管疾患、肺疾患、感染症、内分泌疾患、腫瘍疾患）;アプリケーション（ファーストオーダーターゲティング、セカンドオーダーターゲティング、サードオーダーターゲティング）;エンドユーザー（病院、クリニック、その他エンドユーザー）

調査対象企業の例（注目の32社）

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Becton Dickinson and Company
  • Bristol-Myers Squibb
  • Camurus AB
  • Confo Therapeutics
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • Evox Therapeutics Ltd
  • Genmab A/S
  • GlaxoSmithKline plc
  • ImmunoGen, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision NanoSystems Inc.
  • Seagen Inc.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP34411

Global Targeted Drug Delivery Market to Reach US$24.9 Billion by 2030

The global market for Targeted Drug Delivery estimated at US$10.0 Billion in the year 2024, is expected to reach US$24.9 Billion by 2030, growing at a CAGR of 16.5% over the analysis period 2024-2030. Cardiovascular Diseases, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Pulmonary Diseases segment is estimated at 16.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 15.6% CAGR

The Targeted Drug Delivery market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 14.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.3% CAGR.

Global Targeted Drug Delivery Market - Key Trends & Drivers Summarized

Why Is Targeted Drug Delivery Transforming Therapeutic Precision and Systemic Safety in Modern Medicine?

Targeted drug delivery systems are revolutionizing the way therapeutic agents are administered by directing drugs specifically to diseased tissues or cells, thereby minimizing systemic exposure and associated side effects. Unlike conventional systemic therapies, which often impact healthy tissues, targeted approaches improve drug concentration at the site of action, enhance therapeutic efficacy, and reduce off-target toxicity. This shift is particularly crucial in oncology, neurology, and immunology, where treatment specificity can significantly influence patient outcomes.

The appeal of targeted drug delivery lies not only in clinical efficiency but also in its potential to reduce dosage frequency, increase bioavailability, and overcome biological barriers such as the blood-brain barrier or tumor microenvironment. By enhancing drug localization, these systems are redefining how chronic diseases, genetic disorders, and complex pathologies are managed-supporting the transition from generalized to precision medicine. As demand for personalized treatment continues to rise, targeted delivery is increasingly central to pharmaceutical innovation and patient-centric care.

How Are Nanotechnology, Biomaterials, and Smart Carriers Enhancing Targeted Drug Delivery Platforms?

Advancements in nanotechnology and biomaterials are enabling the development of highly engineered carriers-such as liposomes, dendrimers, polymeric nanoparticles, and antibody-drug conjugates-that improve drug stability, control release kinetics, and facilitate selective targeting. These systems can be surface-functionalized with ligands, antibodies, or peptides to bind specifically to receptors expressed on diseased cells, enabling receptor-mediated uptake and intracellular delivery of payloads with high precision.

Smart delivery systems are also being developed to respond to physiological stimuli-such as pH, enzymes, or temperature-ensuring drug activation only under specific conditions within diseased tissue. Such stimulus-responsive platforms enhance drug control, reduce premature degradation, and support localized therapeutic actions. Emerging innovations, including exosome-based delivery and CRISPR-loaded nanoparticles, are pushing the frontiers of targeted delivery by combining biological compatibility with molecular-level control, opening new pathways for treating previously inaccessible conditions.

Which Therapeutic Areas and Delivery Routes Are Driving Demand for Targeted Drug Delivery Solutions?

Oncology remains the largest application area for targeted drug delivery due to the need for site-specific chemotherapy, immunotherapy, and radiopharmaceuticals. Technologies such as antibody-drug conjugates and nanoparticle-based formulations are enabling selective tumor targeting, improving treatment response rates and reducing systemic side effects. Similarly, targeted delivery is gaining traction in central nervous system (CNS) disorders, where crossing the blood-brain barrier remains a significant challenge for conventional drugs.

Beyond oncology and neurology, autoimmune diseases, infectious diseases, and rare genetic disorders are emerging as high-growth segments. Intravenous administration remains dominant for systemic targeting, but oral, intranasal, transdermal, and implantable routes are being developed for localized or sustained release applications. The expansion of delivery modalities tailored to disease-specific needs is increasing the versatility of targeted systems, making them viable across a broader spectrum of indications and patient populations.

How Are Regulatory Pathways, Market Access, and Clinical Translation Influencing Commercialization?

Targeted drug delivery products must navigate complex regulatory pathways due to their novel mechanisms, composite structures, and potential safety concerns. Agencies such as the FDA and EMA are refining guidance for nanomedicine and combination products, focusing on aspects like pharmacokinetics, toxicity profiling, and product characterization. Early engagement with regulators, robust clinical evidence, and quality-by-design (QbD) approaches are becoming critical for accelerating approval and ensuring reproducibility at scale.

Market access is equally dependent on cost-effectiveness, manufacturing scalability, and clinical adoption. While targeted therapies often carry high development costs, their ability to improve outcomes and reduce downstream treatment burdens can support favorable health economics. Collaborations between drug developers, device companies, and delivery technology providers are becoming more common to bridge scientific innovation and commercial viability. As real-world data and personalized diagnostics expand, payer and clinician acceptance of targeted drug delivery solutions is gaining traction across global healthcare markets.

What Are the Factors Driving Growth in the Targeted Drug Delivery Market?

The targeted drug delivery market is growing rapidly as pharmaceutical innovation pivots toward precision medicine, and as healthcare systems seek therapies that maximize efficacy while minimizing systemic burden. Advances in nanocarrier engineering, biomolecular targeting, and drug conjugation technologies are expanding therapeutic potential across multiple disease categories. Simultaneously, the promise of personalized, tissue-specific treatments is aligning with regulatory incentives, academic research, and commercial partnerships.

Looking ahead, market momentum will depend on how effectively developers can integrate delivery innovations with therapeutic pipelines, meet evolving regulatory standards, and demonstrate clinical and economic value. As treatment paradigms shift toward more individualized, mechanism-based interventions, targeted drug delivery is poised to become a foundational enabler of next-generation medicine-driving growth at the nexus of technology, biology, and patient-centered care.

SCOPE OF STUDY:

The report analyzes the Targeted Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases, Oncological Disorders); Application (First Order Targeting, Second Order Targeting, Third Order Targeting); End-User (Hospitals, Clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Becton Dickinson and Company
  • Bristol-Myers Squibb
  • Camurus AB
  • Confo Therapeutics
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • Evox Therapeutics Ltd
  • Genmab A/S
  • GlaxoSmithKline plc
  • ImmunoGen, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision NanoSystems Inc.
  • Seagen Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Targeted Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Precision Medicine and Oncology Drive Rapid Innovation in Targeted Drug Delivery Technologies
    • Nanocarriers, Liposomes, and Antibody-Drug Conjugates Enable Site-Specific Therapeutic Delivery
    • Regulatory Approvals of mRNA and Lipid Nanoparticle Platforms Accelerate Adoption in Non-Viral Modalities
    • Reduced Off-Target Effects and Enhanced Bioavailability Strengthen Use in Rare and Chronic Conditions
    • Integration of Imaging-Guided and pH-Sensitive Delivery Systems Enhances Tumor Selectivity
    • Biotech Startups Focus on Ligand-Targeted and Receptor-Specific Drug Delivery Innovations
    • Inhalable, Transdermal, and Injectable Formats Expand Application in Pain, CNS, and Autoimmune Disorders
    • Controlled Release Technologies Improve Dosing Compliance and Patient Outcomes
    • R&D in RNA, CRISPR, and Gene Therapy Expands Scope for Targeted Nucleic Acid Delivery
    • Smart Polymers and External Stimuli (e.g., magnetic, ultrasonic) Open New Frontiers in Precision Delivery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Targeted Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Targeted Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Targeted Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Pulmonary Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Pulmonary Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Endocrine Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Endocrine Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for First Order Targeting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for First Order Targeting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Second Order Targeting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Second Order Targeting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Third Order Targeting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Third Order Targeting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • JAPAN
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • CHINA
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • EUROPE
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Targeted Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Targeted Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • FRANCE
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • GERMANY
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • UNITED KINGDOM
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Targeted Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Targeted Drug Delivery by Disease Type - Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Targeted Drug Delivery by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases and Oncological Disorders for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Targeted Drug Delivery by End-user - Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Targeted Drug Delivery by End-user - Percentage Breakdown of Value Sales for Clinics, Other End-Users and Hospitals for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Targeted Drug Delivery by Application - First Order Targeting, Second Order Targeting and Third Order Targeting - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Targeted Drug Delivery by Application - Percentage Breakdown of Value Sales for First Order Targeting, Second Order Targeting and Third Order Targeting for the Years 2025 & 2030

IV. COMPETITION